IndyGeneUS AI is building the largest blockchain-encrypted repository of indigenous and diasporic African clinical and genomic data, utilizing proprietary technology to analyze multi-omics data alongside electronic health records and scientific literature. This approach enables the identification of novel biomarkers and polygenic risk scores, addressing the lack of diverse genomic data in precision medicine.
Funding
Funding not disclosed
Founders
Product
Problem
The lack of diverse genomic data, particularly from indigenous and diasporic African populations, hinders the development of effective precision medicine and targeted therapies, leading to health disparities. Existing genomic databases often underrepresent these populations, limiting the applicability of research findings and the development of tailored treatments.
Solution
IndyGeneUS AI is developing a blockchain-encrypted repository of clinical and multi-omics data from indigenous and diasporic African populations to address the gap in genomic diversity. The company leverages data mining and artificial intelligence to analyze genomic data alongside electronic health records and scientific literature, accelerating the development and manufacturing of quality targeted therapies. IndyGeneUS AI offers comprehensive contract development and manufacturing organization (CDMO) services, providing a one-stop solution for advanced therapy development, including process development, analytical services, plasmid manufacturing, scalable vector production, cell banking, and cell processing. The platform aims to empower individuals to control, share, and benefit from their genetic data while advancing research to extend healthy human lifespans.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers focused on developing and delivering precision medicine solutions for diverse populations, as well as individuals interested in understanding their genetic predispositions.
Features
- Blockchain-encrypted data repository ensuring secure and transparent data management
- AI-driven analysis of multi-omics data (genomic, proteomic, etc.) integrated with clinical records
- CDMO services for cell and gene therapy development, from pre-clinical to commercial stages
- cGMP manufacturing of viral vectors at commercial scale
- Bioprocessing of autologous and allogeneic cellular therapies
- Extensive analytical development and testing capabilities for advanced therapeutics and biopharmaceuticals
- Streamlined manufacturing of cGMP Master Cell Banks (MCB), Working Cell Banks (WCB), Master Viral Banks (MVB), & Working Viral Banks (WVB)
- Proprietary IndyGeneUS-IQ™ kits for individual genomic data collection and analysis